Akero Therapeutics

The Associate Director will lead late-stage development activities for EFX, focusing on drug product formulations and manufacturing processes. Responsibilities include preparing CMC sections for regulatory submissions and managing drug product activities with external partners.

The Principal Scientist will oversee analytical characterization activities and support regulatory submissions for late-stage biologic development. This includes developing and executing analytical studies, collaborating with cross-functional teams, and engaging with external partners.

The Director/Sr. Director will execute the Phase 3 clinical development program for Efruxifermin (EFX), serving as Medical Monitor, reviewing safety data, and supporting regulatory submissions. Key duties include planning, conducting, and evaluating clinical trials, and contributing to scientific data disclosures and regulatory document authoring.